Zinc Supplementation in Alcoholic Cirrhosis

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if zinc therapy: (1) strengthens your intestine's defensive barrier preventing damaging substances from reaching your liver, (2) decreases liver injury (inflammation, oxidative stress, cell death) and scarring, and (3) improves your liver-related health. Based on our preliminary animal data and other published reports, we expect zinc therapy to achieve all of these goals. Zinc is affordable, available over the counter or by prescription, and has an excellent safety profile. Positive results from this study will show that zinc is a significant therapy for millions of Americans with alcoholic liver disease.

Clinical Trial Description

Two-thirds of Americans consume alcohol, and an estimated 14 million Americans are alcoholics. It has been estimated that 15%-30% of heavy drinkers develop advanced Alcoholic liver disease (ALD). The prevalence of ALD in the United States is conservatively estimated at 2 million persons. Nearly 50% of liver-related deaths and 30% of hepatocellular carcinomas in the US are due to alcoholic cirrhosis. Despite recent advances in our understanding of ALD, there is currently no FDA approved medication for any stage of ALD. Zinc sulfate is inexpensive, available over the counter, and has an excellent safety profile. If zinc positively influences the mechanisms postulated to play a role in human ALD, this affordable treatment would become relevant to millions of people worldwide. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02072746
Study type	Interventional
Source	University of Louisville
Contact
Status	Completed
Phase	N/A
Start date	February 2010
Completion date	March 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04106518` - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Completed	`NCT01065233` - Pangenomic Study During Alcoholic Cirrhosis
Recruiting	`NCT04250259` - SAMe Trial for Patients With Alcoholic Cirrhosis	Phase 2
Active, not recruiting	`NCT01213927` - National Cohort of Uncomplicated Alcoholic Cirrhosis
Completed	`NCT00388323` - Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human	N/A
Terminated	`NCT01342705` - Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis	Phase 3
Recruiting	`NCT04689152` - Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis	Phase 3
Recruiting	`NCT05155657` - Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells	Phase 1
Terminated	`NCT03534141` - Mild Hypothermia and Acute Kidney Injury in Liver Transplantation	N/A
Completed	`NCT00827723` - Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
Recruiting	`NCT04245189` - EUS Based Prevalence of Chronic Pancreatitis in Alcoholic Cirrhosis
Completed	`NCT01756794` - Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment	N/A
Recruiting	`NCT05093881` - Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study	N/A
Terminated	`NCT03508388` - Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
Completed	`NCT02326103` - Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis	Phase 0
Terminated	`NCT00188045` - Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients	Phase 4
Withdrawn	`NCT04070508` - Early Detection of Alcoholic Liver Disease
Recruiting	`NCT04363424` - Alcohol Biomarker Study